Gilead Sciences posted better-than-anticipated earnings for the first quarter. Shares fell anyway.
Pharmaceutical Technology on MSN
Gilead posts positive Q1 buoyed by HIV drug growth
Biktarvy continues to be a strong growth asset for Gilead, while Yeztugo’s launch rides an upward trajectory.
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Gilead Sciences, Inc. is among the best ...
This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science.
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Gilead Sciences Inc. is seeking to knock down a groundbreaking theory of product liability advanced by thousands of patients ...
The Food and Drug Administration on Wednesday approved Gilead's twice-yearly antiviral injection for preventing HIV — a milestone that the company and some experts say could help bring the world ...
May 6 (Reuters) - The California Supreme Court will on Wednesday consider whether manufacturers of drugs that are ...
Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results